AAPG ASCENTAGE PHARMA GROUP INTE...

Nasdaq www.ascentage.com


$ 35.54 $ -1.02 (-2.8 %)    

Friday, 17-Oct-2025 14:15:41 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 35.44
$ 35.82
$ 33.80 x 10
$ 40.00 x 1
$ 35.44 - $ 35.82
$ 17.00 - $ 48.45
1,604
na
12.34B
$ 0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855))) ("Ascentage" or the "Company"), a global ...

Core News & Articles

Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855))), a global biopharmaceutical company dedicated to addressing unmet medical needs in...

 us-stocks-likely-to-open-mixed-as-trump-issues-tariff-letters-experts-peg-ai-investments-as-durable-drivers-of-returns

U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading ...

Core News & Articles

These poster presentations feature five of the company's drug candidates: novel tyrosine kinase inhibitor (TKI) olverembati...

 bitdeer-tech-and-tempus-ai-are-among-top-18-mid-cap-gainers-last-week-apr-21-apr-25-are-the-others-in-your-portfolio

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Ky...

Core News & Articles

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855))), a global bio...

 chinese-biotech-ascentage-pharmas-valuation-driven-by-late-stage-de-risked-assets-jpmorgan

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342%...

Core News & Articles

JP Morgan analyst Brian Cheng initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight rating.

 ipo-momentum-builds-in-2025-diginex-ctrl-group-and-others-post-strong-gains

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION